Embecta (EMBC) Earnings Date & Reports
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more
EMBC is expected to report earnings to 26 cents per share on August 07
Embecta Corp. (EMBC) Q2 Fiscal 2026 Earnings Recap: Shares Plunge on Revenue Miss and Guidance Cut
Key Takeaways
- Embecta Corp. reported Q2 fiscal 2026 revenue of $221.8 million, down 14.4% year-over-year and missing consensus estimates of $235.7 million.
- Adjusted EPS came in at $0.27, significantly below the $0.42 expected by analysts and down from $0.70 in the prior-year quarter.
- U.S. revenue plunged 29.4% due to competitive pressures and market softness, while international revenue rose 2.1% on a reported basis.
- Company slashed full-year FY2026 guidance, now expecting revenue of $1.015–$1.035 billion and adjusted EPS of $1.55–$1.75, down from prior ranges of $1.071–$1.093 billion and $2.80–$3.00.
- Embecta announced a $100 million share repurchase program and reduced its quarterly dividend to $0.01 per share from $0.15.
- Shares tumbled over 57% in response to the disappointing results and lowered outlook.
Earnings Context and Why It Matters
Embecta Corp. (EMBC), a global diabetes care company specializing in injection devices like pen needles and syringes, faces intensifying challenges in its core U.S. market amid rising competition and softening volumes. This Q2 fiscal 2026 earnings report (quarter ended March 31, 2026) is critical as it highlights ongoing pressures following a milder Q1 decline. With over 75% of revenue now under the embecta brand after transitioning from its former parent Becton Dickinson, investors are watching for signs of stabilization in market share and progress in strategic expansions like GLP-1 drug delivery partnerships and the pending Owen Mumford acquisition. The results underscore vulnerabilities in the diabetes injection device sector, where pricing dynamics and customer mix shifts can rapidly erode profitability, making this a pivotal moment for assessing Embecta's path to becoming a broader medical supplies provider.
Embecta reported second quarter fiscal 2026 revenue of $221.8 million, a 14.4% decline from $259.0 million in the year-ago period and below consensus estimates of $235.7 million. The drop was driven primarily by U.S. revenue, which fell 29.4% due to unfavorable volume ($39.3 million impact, mainly pen needle share loss at a key customer), pricing ($3.6 million), and lower contract manufacturing, partially offset by favorable foreign exchange. International revenue grew 2.1% reported (down 4.1% adjusted constant currency), aligning with expectations.
Adjusted gross margin contracted to 59.4% from 63.7%, reflecting pricing and mix pressures. Adjusted operating income dropped to $48.6 million (21.9% margin) from $81.4 million (31.4% margin). GAAP net loss was $4.1 million, or $(0.07) per diluted share, versus net income of $23.5 million, or $0.40 per share, last year. Adjusted net income was $16.1 million, or $0.27 per diluted share—well short of the $0.42 consensus and down from $0.70 prior year.
Key metrics included adjusted EBITDA of $64.6 million (29.1% margin) versus $97.1 million (37.5%) last year. The company also announced plans for ~$150 million in debt repayment in FY2026 and initiated a cost structure review.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
Embecta's shares cratered more than 57% on May 5, 2026, closing around $3.89 after plummeting from the prior close near $9.25, reflecting sharp disappointment over the earnings miss and drastically lowered guidance. Premarket trading saw drops exceeding 50%, driven by U.S. weakness and concerns over sustained competitive dynamics. Investor sentiment turned bearish, with focus on the ~$75 million full-year revenue guidance reduction (70% from pen needles) and EPS outlook halved, overshadowing positives like the Owen Mumford deal and buyback authorization.
Forward Outlook and Key Factors to Monitor
Embecta significantly lowered its FY2026 guidance, now projecting reported revenue of $1.015–$1.035 billion (down from $1.071–$1.093 billion), implying adjusted organic constant currency growth of (10.2)%–(8.3)% after a 1.5% foreign exchange tailwind. Adjusted operating margin is expected at 22.25%–23.25% (down from 29.0%–30.0%), with adjusted EPS of $1.55–$1.75 (from $2.80–$3.00). Free cash flow guidance was also cut to $95–$105 million. These updates incorporate ongoing U.S. headwinds and ~$0.15 EPS dilution from the Owen Mumford acquisition, expected to close in May 2026 and add ~$30 million in revenue.
Investors should monitor the outcome of Embecta's cost structure and organizational footprint review, with updates forthcoming. Progress on the $100 million three-year share repurchase program and sustained debt reduction (~$150 million planned) will signal capital allocation priorities, alongside the dividend cut to $0.01 quarterly for flexibility.
On the growth front, track brand transition completion (targeted end-2026), GLP-1 business-to-business (B2B) pipeline (40% of partners advancing), and new product launches like syringes in China and pen needles pending approvals. The Owen Mumford deal broadens into auto-injectors and pharma services, potentially offsetting core insulin delivery declines amid competitive pressures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
Industry PharmaceuticalsOther